BioSpace News Archive

Soligenix, Inc. announced today that the European Patent Office has granted a patent entitled “Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis”.

Aviceda Therapeutics today announced the appointment of Patrick Johnson to its board of directors.

Covalon Technologies Ltd. today announced it is a silver sponsor of the 2023 Neonatal/Fetal Conference: From the Womb and Beyond being held both virtually and in-person in Columbus, Ohio from May 17 to 19, 2023.

Inhibikase Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 2 ‘201' trial evaluating IkT-148009, the Company’s novel Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.

Shorla Oncology today announced the commercial launch of the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) (“Altamira” or the “Company”), a company dedicated to addressing unmet medical needs, today provided a business update and reported its full year 2022 financial results ended December 31, 2022.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) announced today that its management team will participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series on Monday, May 22, 2023.

Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that it has shipped its 100thCytek Aurora CS system.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, will present positive preclinical data from studies of AVB-202, the company’s gene therapy candidate for the treatment of Friedreich’s Ataxia (FA).

Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need.